trending Market Intelligence /marketintelligence/en/news-insights/trending/0zjoeoslmllricnqju7fhg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

US FDA approves Dexcom's glucose monitoring system

Street Talk Episode 51 - Goldman Talks Libor Transition, Recent SOFR Volatility

#ChangePays: Although Still Underrepresented, Women in the C-Suite are Driving Profitability

Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles

Energy

Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018


US FDA approves Dexcom's glucose monitoring system

The U.S. FDA approved DexCom Inc.'s G5 Mobile CGM system, a continuous glucose monitoring system, with a non-adjunctive designation.

In July, an FDA selected panel of experts deemed the system safe and effective, with its benefits outweighing the risks with the proposed indications for use. The FDA has followed the expert recommendation and made the system the first and only continuous glucose monitoring system in the U.S. to have a non-adjunctive designation.

The new non-adjunctive indication expands the use of the system as a replacement to finger stick glucose testing for diabetes treatment decisions. With the new label indication, the system only requires two finger pricks per day for calibration.